Moreover, these anticancer effects havebeen observed with concentrations of PPARγ agonists which are not only higher thanthe clinical doses used for T2D treatment but also affect PPAR α and δ isoforms, being no longer selective for PPARγ. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.